

## SRS 2026- Hollywood, FL- JULY 26<sup>th</sup>

### SRS 2026 Uro-oncology program (Bladder and Kidney)

The SRS Uro-Oncology Course aims to integrate multiple specialties, including urology, medical oncology, radiation oncology, radiology, pathology, and genomic medicine, to discuss the most contemporary and evidence-based approaches to the management of uro-oncologic patients. Our objective is to provide a multidisciplinary educational platform built on the highest level of clinical and scientific evidence, encouraging collaboration among experts, residents, and fellows. This comprehensive program also creates opportunities for engagement with companies involved in imaging, artificial intelligence, genetic testing, and novel therapeutics, promoting innovation and educational impact across the field of uro-oncology.

#### **Faculty**

Brian Miles, MD  
Marcio Moschovas, MD, PhD  
Guru Sonpavde, MD  
Raj Pruthi, MD  
Daher Chade, MD  
Bridget Koontz, MD  
Alexandre Pompeo, MD  
Fernando Maluf, MD  
Christopher Russel, MD  
Justin Emtage, MD

*We will add more faculty*

#### **Bladder Cancer (4 Hours)**

**07:50–08:00** – Welcome and Introduction to the Course

**08:00–08:20** – State-of-the-Art in Bladder Cancer (2025–2026)

*Guru Sonpavde, MD*

Recent updates from NCCN, AUA, and EAU guidelines; integration of imaging, genomics, and radioligand therapy into standard of care.

---

#### **Module 1 – NMIBC (08:20–09:35)**

##### **Novel Approaches in the Diagnosis and Treatment of NMIBC (90 Minutes)**

- **08:20–08:35** – Urine-Based Biomarkers: Past, Present, and Future  
*(Possible support from Vesica, Convergent)*

- **08:35–08:50** – The Role of AI Pathology as a Diagnostic and Predictive Tool  
*(Possible support from Valar Labs)*
  - **08:50–09:05** – Optimizing TURBT: En Bloc Resection  
*(Multiple companies, e.g., Stryker, Hybrid Knife)*
  - **09:05–09:20** – Optimizing TURBT: Robotics  
*(e.g., Agilis Robotics, Virtuoso)*
  - **09:20–09:35** – Case Presentations and Q&A (15 Minutes)
- 

## **Module 2 – Neoadjuvant and Adjuvant Therapies in NMIBC (09:40–11:40)**

- **09:40–10:00** – Guidelines-Based Approach to NMIBC: Met and Unmet Needs
  - **10:00–10:15** – Current Scenario of Bladder Cancer Treatment With BCG Shortages  
*(Possible support from Pfizer)*
  - **10:15–10:30** – Approved Agents in NMIBC  
*(Possible support from J&J, Ferring, ImmunityBio, Merck, Pfizer, UGN; content to be adjusted based on support)*
  - **10:30–10:50** – Agents in Development (20 Minutes)  
*(Possible support from CG Oncology, Relmada Therapeutics, enGene)*
  - **10:50–11:10** – Sequencing and Combining Therapies: Where, When, and How
  - **11:10–11:40** – Case Presentations and Q&A
- 

**11:40–12:10** – Break / Lunch

---

## **Module 3 – Muscle-Invasive Bladder Cancer (12:10–13:10)**

- **12:10–12:20** – Muscle-Invasive Bladder Cancer: Current and Evolving Neoadjuvant/Adjuvant Therapy
  - **12:20–12:30** – Adjuvant Therapy for High-Risk Muscle-Invasive Urothelial Carcinoma  
*(Nivolumab, Pembrolizumab)*
  - **12:30–12:40** – Using ctDNA to Guide Adjuvant Therapy: Universal vs. Selective Use
  - **12:40–12:50** – Bladder Preservation in MIBC: Current Status and Future Directions
  - **12:50–13:00** – Clinical Case Discussion in MIBC
  - **13:00–13:10** – Panel Discussion and Audience Q&A
- 

## **Module 4 – Metastatic Urothelial Carcinoma (13:10–14:10)**

- **13:10–13:20** – Impact of Recent Data on First-Line Therapy
- **13:20–13:30** – Current and Evolving Salvage Therapy
- **13:30–13:40** – Integration of Local Treatment in Advanced Disease
- **13:40–13:55** – Clinical Case Discussion in Metastatic Disease
- **13:55–14:10** – Panel Discussion and Audience Q&A

---

**14:10–14:25** – Break

---

## **Kidney Cancer (4 Hours)**

### **Module 1 – Localized Kidney Cancer (14:25–15:25)**

- **14:25–14:35** – Surgery: Role of Partial Nephrectomy
  - **14:35–14:45** – Role of Non-Surgical Local Definitive Therapy
  - **14:45–14:55** – Neoadjuvant Therapy in Locally Advanced RCC: Is There a Role?
  - **14:55–15:05** – Current and Emerging Adjuvant Therapy for RCC
  - **15:05–15:15** – MRD Detection to Select Patients for Adjuvant Therapy
  - **15:15–15:25** – Panel Discussion and Audience Q&A (10 Minutes)
- 

### **Module 2 - First-Line Therapy for Metastatic RCC (15:25–16:25 | 60 Minutes)**

- **15:25–15:35** – Selecting First-Line Therapy for Clear Cell RCC: IO-IO vs. TKI-IO
  - **15:35–15:45** – Integration of Focal Treatment in Advanced Disease
  - **15:45–15:55** – Role of Cytoreductive Nephrectomy in Metastatic RCC
  - **15:55–16:05** – Therapy for Non-Clear Cell RCC
  - **16:05–16:25** – Clinical Discussions in Metastatic Disease (First-Line Setting)
- 

### **Module 3 - Salvage Systemic Therapy for Metastatic RCC (16:25–17:25)**

- **16:25–16:35** – Salvage Therapy for Clear Cell RCC
- **16:35–16:45** – Salvage Therapy for Non-Clear Cell RCC
- **16:45–16:55** – Sequencing Therapy in Metastatic RCC
- **16:55–17:10** – Clinical Discussions in Metastatic Disease (Second-Line Setting)